The abstract is read at the publisher; the summary is JClub's.
P2RX5-FL is expressed by up to 75% of individuals with African ancestry and is stable on the plasma membrane, enabling CAR T targeting.
- Why it matters: Protein-truncating mutations were thought to make human P2RX5 a pseudogene, leaving direct CAR T targeting untested despite its HLA-restricted antigen potential.
- What they did: Using transcriptomic datasets and newly developed monoclonal antibodies, the authors identified full-length expression and upregulation in BCL, MM, and T-ALL, then built a P2RX5-directed CAR (CART-X5).
- The result: CART-X5 avoided fratricide and reduced disease burden while extending survival in xenograft mouse models of T-ALL and MM, nominating P2RX5-FL for relapsed BCL/MM after CD19 or BCMA therapy and for chemoresistant T-ALL.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.